A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc's breast-cancer drug Enhertu violated Seagen's patent rights.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5,010 JPY | +5.12% | +8.07% | +29.39% |
Apr. 25 | Scholz pledges further support for the pharmaceutical industry | DP |
Apr. 25 | Daiichi Sankyo's Attributable Profit Soars 84% in Fiscal 2024 | MT |
(Reuters) - Seagen Inc said on Friday an arbitrator had ruled in favor of Japan's Daiichi Sankyo over an agreement between the two companies for using Seagen's drug technology.
A Texas jury in April awarded Seagen nearly $42 million from Daiichi Sankyo over claims that Daiichi and AstraZeneca plc's breast-cancer drug Enhertu violated Seagen's patent rights.
(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)
1st Jan change | Capi. | |
---|---|---|
+29.39% | 58.76B | |
+24.35% | 653B | |
+26.00% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.83% | 233B | |
+5.04% | 201B | |
-10.02% | 193B | |
-6.47% | 144B |